Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, January 8, 2010

Teva Pharma Sees Copaxone Pressure Coming But Not from Generic


NEW YORK -(Dow Jones)-. (TEVA) doesn't expect generic competition for its blockbuster multiple sclerosis treatment Copaxone before 2014, but the company warned that competition from oral MS drugs will likely pressure sales before that time.

The Copaxone battle is notable because it pits the world largest generics company, which has benefited from challenging the patents of other pharmaceutical companies, against generic competitors to protect the exclusivity of its own brand.

Momenta Pharmaceuticals Inc. (MNTA) and Mylan Inc. (MYL) have both filed to produce generic versions of Copaxone, a process that is likely to span years. The drug, one of the world's best selling MS treatments with 2008 sales of $2.26 billion, is a key component of Teva's business.

Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: . - Thank you
Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You

No comments: